Risankizumab Effective Through 100 Weeks in Improving Signs,

These data suggest risankizumab was both safe and efficacious through 100 weeks for PsA patients, with no new safety signals.

Related Keywords

Monash , South Australia , Australia , , Monash University Department , American College Of Rheumatology , Monash University , American College , Active Psoriatic Arthritis , Week Results , Rheumatol Ther , Risankizumab , Psoriatic Arthritis , Psa , Signs , Symptoms , 100 Weeks ,